Sensus Healthcare Reports Third Quarter 2022 Financial Results
Sensus Healthcare (SRTS) reported a 64% increase in revenues to $9.0 million for Q3 2022, compared to $5.5 million in Q3 2021. Net income rose to $1.8 million or $0.11 per diluted share, up from $0.2 million or $0.01 per share a year earlier. The company exited Q3 with $37.6 million in cash and no debt. Adjusted EBITDA improved to $2.3 million from $0.5 million. Despite economic headwinds and Hurricane Ian's impact, Sensus expects continued growth and profitability for the fourth quarter.
- Revenues for Q3 2022 increased by 64% to $9.0 million.
- Net income rose to $1.8 million, or $0.11 per diluted share, compared to $0.2 million, or $0.01 per share, year-over-year.
- Exited Q3 with $37.6 million in cash and no debt.
- Adjusted EBITDA increased to $2.3 million from $0.5 million in Q3 2021.
- Launch of Silk™ laser hair removal system at the Fall Clinical Dermatology Conference.
- Significant interest in TransDermal Infusion System presented at the same conference.
- Higher interest rates affecting physician ROI.
- Potential impact on fourth-quarter sales due to Hurricane Ian affecting clinic operations.
Profitability continues with revenues up
Conference call begins at 4:30 p.m. Eastern time today
BOCA RATON, Fla., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces financial results for the three and nine months ended September 30, 2022.
Highlights from the third quarter of 2022 and recent weeks include the following (all comparisons are with the third quarter of 2021, unless otherwise indicated):
- Revenues were
$9.0 million , up64% from$5.5 million - Net income was
$1.8 million , or$0.11 per diluted share, compared with$0.2 million , or$0.01 per diluted share - Exited the quarter with
$37.6 million in cash and cash equivalents, and no debt - Adjusted EBITDA, a non-GAAP financial measure, was
$2.3 million , compared with$0.5 million - Introduced the Silk™ laser hair removal system with blended wavelengths for all skin phototypes at the Fall Clinical Dermatology Conference
- Two key opinion leaders presented research with the TransDermal Infusion (TDI) System™ in delivering finasteride for hair growth and onabotulinumtoxinA for hyperhidrosis at the Fall Clinical Dermatology Conference
- Launched upgrades to the SRT-100 Vision™ system with new state-of-the-art, solid-state, high-frequency ultrasound and a new, ergonomically designed probe
- Shipped the first of 10 TDI Systems ordered by Hair Enhancement Centers to provide needleless injections of U.SK Under Skin’s hair-growth serum Skin Savers Hair™
- Shipped four SRT units to China
- Expects continued growth in the fourth quarter and full-year profitability, noting economic headwinds and the impact of Hurricane Ian on several large customers in Florida
Management Commentary
“We continued to execute very well on our strategy and once again generated strong growth in revenues and profits,” said Joe Sardano, chairman and chief executive officer of Sensus Healthcare. “We remain focused on our core dermatology business, providing products our customers and their patients need. To that end, we launched important upgrades to our premium SRT-100 Vision system that included new state-of-the-art, solid-state, high-frequency ultrasound, which provides the best view of the epidermis in the market and utilizes a new ergonomically designed probe employing single-use disposables. The Vision model has become our leading SRT product, helped by these design upgrades and our fair market leasing program. That said, higher interest rates are impacting physician ROI, but not demand.”
Mr. Sardano added, “Our recently acquired TransDermal Infusion System for the needleless and pain-free delivery of aesthetic medicines is generating significant attention at tradeshows and medical conferences. Research by key opinion leaders Dr. Mark Nestor and Dr. Glynis Ablon continues to support our marketing efforts. At the Fall Clinical Dermatology Conference, Dr. Nestor presented his success with the TDI System to deliver onabotulinumtoxinA, better known as Botox, in hyperhidrosis patients, and Dr. Ablon presented on the ability of the TDI System to deliver finasteride, better known as Propecia, for hair growth without pain. During the third quarter we took orders for 10 TDI Systems from Hair Enhancement Centers, delivered one during the quarter and expect to deliver the remaining nine before the end of the year.
“We continued to see good uptake on our service agreements, with approximately
Third Quarter Financial Results
Revenues for the third quarter of 2022 were
Cost of sales for the third quarter of 2022 was
Gross profit for the third quarter of 2022 was
Selling and marketing expense for the third quarter of 2022 was
General and administrative expense for the third quarter of 2022 was
Research and development expense for the third quarter of 2022 was
Provision for income taxes was
Net income for the third quarter of 2022 was
Adjusted EBITDA for the third quarter of 2022 was
Cash and cash equivalents were
Nine Month Financial Results
Revenues for the first nine months of 2022 were
Cost of sales was
Gross profit for the first nine months of 2022 was
Selling and marketing expense was
General and administrative expense was
Research and development expense of
The Company reported other income of
Net income for the first nine months of 2022 was
Adjusted EBITDA for the first nine months of 2022 was
Use of Non-GAAP Financial Information
This press release contains supplemental financial information determined by methods other than in accordance with accounting principles generally accepted in the United States (GAAP). Sensus Healthcare management uses Adjusted EBITDA, a non-GAAP financial measure, in its analysis of performance. Adjusted EBITDA should not be considered a substitute for GAAP basis measures, nor should it be viewed as a substitute for operating results determined in accordance with GAAP. Management believes the presentation of Adjusted EBITDA, which excludes the impact of interest, income taxes, depreciation, amortization and stock-compensation expense, provides useful supplemental information that is essential to a proper understanding of the financial results of Sensus Healthcare. Non-GAAP financial measures are not formally defined by GAAP, and other entities may use calculation methods that differ from those used by Sensus Healthcare. As a complement to GAAP financial measures, management believes that Adjusted EBITDA assists investors who follow the practice of some investment analysts who adjust GAAP financial measures to exclude items that may obscure underlying performance and distort comparability. A reconciliation of the GAAP net loss to Adjusted EBITDA is provided in the schedule below.
| SENSUS HEALTHCARE, INC. | |||||||||||||||
| GAAP TO NON-GAAP RECONCILIATION | |||||||||||||||
| (unaudited) | |||||||||||||||
| For the Three Months Ended | For the Nine Months Ended | ||||||||||||||
| September 30, | September 30, | ||||||||||||||
| (in thousands) | 2022 | 2021 | 2022 | 2021 | |||||||||||
| Net income (loss), as reported | $ | 1,829 | $ | 195 | $ | 21,415 | $ | (1,199 | ) | ||||||
| Add: | |||||||||||||||
| Depreciation and amortization | 75 | 127 | 241 | 472 | |||||||||||
| Stock compensation expense | 40 | 204 | 137 | 324 | |||||||||||
| Income Tax | 450 | - | 2,168 | - | |||||||||||
| Interest, net | (118 | ) | - | (145 | ) | - | |||||||||
| Adjusted EBITDA, non GAAP | $ | 2,276 | $ | 526 | $ | 23,816 | $ | (403 | ) | ||||||
Conference Call and Webcast
Sensus Healthcare will host an investment community conference call today beginning at 4:30 p.m. Eastern time during which management will discuss financial results for the third quarter of 2022, provide a business update and answer questions. To access the conference call, dial 866-777-2509 (U.S. and Canada Toll Free) or 412-317-5413 (International). The call will be webcast live and can be accessed at this link, or in the Investors section of the Company’s website at www.sensushealthcare.com.
Following the conclusion of the conference call, a replay will be available until December 3rd and can be accessed by dialing 877-344-7529 (U.S. Toll Free), 855-669-9658 (Canada Toll Free) or 412-317-0088 (International), using replay code 4619519. An archived webcast of the call will also be available in the Investors section of the Company’s website.
About Sensus Healthcare
Sensus Healthcare, Inc. is a medical device company specializing in highly effective, non-invasive, minimally invasive and cost-effective treatments for both oncological and non-oncological conditions. Sensus offers its proprietary low-energy X-ray technology known as superficial radiation therapy (SRT), which is the culmination of more than a decade of research and development, to treat non-melanoma skin cancers and keloids with its SRT-100™, SRT-100+™ and SRT-100 Vision™ systems. With its portfolio of innovative medical device products, including aesthetic lasers and its needleless TransDermal Infusion System™, Sensus provides revolutionary treatment options to enhance the quality of life of patients around the world.
For more information, visit www.sensushealthcare.com.
Forward-Looking Statements
This press release includes statements that are, or may be deemed, ''forward-looking statements.'' In some cases, these statements can be identified by the use of forward-looking terminology such as "believes," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should," “approximately,” "potential" or negative or other variations of those terms or comparable terminology, although not all forward-looking statements contain these words.
Forward-looking statements involve risks and uncertainties because they relate to events, developments, and circumstances relating to Sensus, our industry, and/or general economic or other conditions that may or may not occur in the future or may occur on longer or shorter timelines or to a greater or lesser degree than anticipated. Although we believe that we have a reasonable basis for each forward-looking statement contained in this press release, forward-looking statements are not guarantees of future performance, and our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate may differ materially from the forward looking statements contained in this press release, as a result of the following factors, among others: the continuation and severity of the COVID-19 pandemic, including its impact on sales and marketing; our ability to achieve profitability; our ability to obtain and maintain the intellectual property needed to adequately protect our products, and our ability to avoid infringing or otherwise violating the intellectual property rights of third parties; the level and availability of government and/or third party payor reimbursement for clinical procedures using our products, and the willingness of healthcare providers to purchase our products if the level of reimbursement declines; the regulatory requirements applicable to us and our competitors; our ability to efficiently manage our manufacturing processes and costs; the risks arising from doing business in China and other foreign countries; legislation, regulation, or other governmental action that affects our products, taxes, international trade regulation, or other aspects of our business; concentration of our customers in the U.S. and China, including the concentration of sales to one particular customer in the U.S.; and other risks described from time to time in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q.
At the present time, we do not expect that the Russian invasion of Ukraine and global geopolitical uncertainty will have any particular impact on our business, but we continue to monitor developments and will address them in future disclosures, if applicable.
In addition, even if future events, developments, and circumstances are consistent with the forward-looking statements contained in this press release, they may not be predictive of results or developments in future periods. Any forward-looking statements that we make in this press release speak only as of the date of such statement, and we undertake no obligation to update such statements to reflect events or circumstances after the date of this press release, except as may be required by applicable law. You should read carefully our "Introductory Note Regarding Forward-Looking Information" and the factors described in the "Risk Factors" section of our periodic reports filed with the Securities and Exchange Commission to better understand the risks and uncertainties inherent in our business.
Contact:
LHA Investor Relations
Kim Sutton Golodetz
212-838-3777
kgolodetz@lhai.com
(Tables to follow)
| SENSUS HEALTHCARE, INC. | ||||||||||||||||
| CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS | ||||||||||||||||
| For the Three Months Ended | For the Nine Months Ended | |||||||||||||||
| (in thousands, except share and per share data) | September 30, | September 30, | ||||||||||||||
| 2022 | 2021 | 2022 | 2021 | |||||||||||||
| (unaudited) | (unaudited) | (unaudited) | (unaudited) | |||||||||||||
| Revenues | $ | 9,010 | $ | 5,525 | $ | 31,428 | $ | 14,017 | ||||||||
| Cost of sales | 3,136 | 2,324 | 10,150 | 5,885 | ||||||||||||
| Gross profit | 5,874 | 3,201 | 21,278 | 8,132 | ||||||||||||
| Operating expenses: | ||||||||||||||||
| Selling and marketing | 1,807 | 1,180 | 4,753 | 3,502 | ||||||||||||
| General and administrative | 1,160 | 1,082 | 3,564 | 3,499 | ||||||||||||
| Research and development | 746 | 744 | 2,302 | 2,330 | ||||||||||||
| Total operating expenses | 3,713 | 3,006 | 10,619 | 9,331 | ||||||||||||
| Income (loss) from operations | 2,161 | 195 | 10,659 | (1,199 | ) | |||||||||||
| Other income (expense): | ||||||||||||||||
| Gain on sale of assets | - | - | 12,779 | - | ||||||||||||
| Interest income | 119 | - | 147 | 1 | ||||||||||||
| Interest expense | (1 | ) | - | (2 | ) | (1 | ) | |||||||||
| Other income (expense), net | 118 | - | 12,924 | - | ||||||||||||
| Net Income (loss) before income tax | 2,279 | 195 | 23,583 | (1,199 | ) | |||||||||||
| Provision for income tax | 450 | - | 2,168 | - | ||||||||||||
| Net income (loss) | $ | 1,829 | $ | 195 | $ | 21,415 | $ | (1,199 | ) | |||||||
| Net income (loss) per share - basic | $ | 0.11 | $ | 0.01 | $ | 1.30 | $ | (0.07 | ) | |||||||
| - diluted | $ | 0.11 | $ | 0.01 | $ | 1.28 | $ | (0.07 | ) | |||||||
| Weighted average number of shares used in computing net income (loss) per share - basic | 16,478,742 | 16,486,969 | 16,498,557 | 16,470,258 | ||||||||||||
| - diluted | 16,648,229 | 16,498,832 | 16,689,548 | 16,470,258 | ||||||||||||
| SENSUS HEALTHCARE, INC. | ||||||||
| CONDENSED CONSOLIDATED BALANCE SHEETS | ||||||||
| As of September 30, | As of December 31, | |||||||
| (in thousands, except shares and per share data) | 2022 | 2021 | ||||||
| (unaudited) | ||||||||
| Assets | ||||||||
| Current assets | ||||||||
| Cash and cash equivalents | $ | 37,577 | $ | 14,519 | ||||
| Accounts receivable, net | 7,396 | 12,130 | ||||||
| Inventories | 2,350 | 1,759 | ||||||
| Prepaid and other current assets | 4,207 | 2,837 | ||||||
| Total current assets | 51,530 | 31,245 | ||||||
| Property and equipment, net | 474 | 605 | ||||||
| Intangibles, net | 74 | 146 | ||||||
| Deposits | 36 | 75 | ||||||
| Deferred tax asset | 1,602 | - | ||||||
| Operating lease right-of-use assets, net | 1,043 | 169 | ||||||
| Total assets | $ | 54,759 | $ | 32,240 | ||||
| Liabilities and stockholders' equity | ||||||||
| Current liabilities | ||||||||
| Accounts payable and accrued expenses | $ | 4,883 | $ | 4,058 | ||||
| Product warranties | 302 | 508 | ||||||
| Operating lease liabilities, current portion | 220 | 174 | ||||||
| Loan payable | - | 51 | ||||||
| Income tax payable | 233 | - | ||||||
| Deferred revenue, current portion | 1,012 | 1,172 | ||||||
| Total current Liabilities | 6,650 | 5,963 | ||||||
| Operating lease liabilities, net of current portion | 846 | - | ||||||
| Deferred revenue, net of current portion | 139 | 262 | ||||||
| Total liabilities | 7,635 | 6,225 | ||||||
| Commitments and contingencies | ||||||||
| Stockholders' equity | ||||||||
| Preferred stock, 5,000,000 shares authorized and none issued and outstanding | - | - | ||||||
| Common stock, issued and 16,617,274 outstanding at December 31, 2021 | 169 | 167 | ||||||
| Additional paid-in capital | 44,921 | 44,115 | ||||||
| Treasury stock, 213,656 and 77,037 shares at cost, at September 30, 2022 and December 31, 2021, respectively | (1,439 | ) | (325 | ) | ||||
| Retained earnings (Accumulated deficit) | 3,473 | (17,942 | ) | |||||
| Total stockholders' equity | 47,124 | 26,015 | ||||||
| Total liabilities and stockholders' equity | $ | 54,759 | $ | 32,240 | ||||
FAQ
What were the financial results for SRTS in Q3 2022?
What is SRTS's diluted EPS for Q3 2022?
What was the Adjusted EBITDA for SRTS in the third quarter of 2022?
How much cash did SRTS have at the end of Q3 2022?
What is the outlook for SRTS following Q3 2022 results?
